+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin therapy in the secondary prevention of cerebrovascular events: is it really beneficial in clinical practice?

Statin therapy in the secondary prevention of cerebrovascular events: is it really beneficial in clinical practice?

Medical Hypotheses 74(2): 398

(PDF emailed within 0-6 h: $19.90)

Accession: 055911271

Download citation: RISBibTeXText

PMID: 19733010

DOI: 10.1016/j.mehy.2009.08.010

Related references

Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. Plos One 9(11): E111247, 2015

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385(9984): 2264-2271, 2015

Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice. Journal of Pharmacy Practice 20(2): 117-122, 2007

A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences 23(5): 2302-2310, 2019

Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events. Journal of Cardiovascular Medicine 19(7): 373-381, 2018

Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease. Journal of Vascular Surgery 50(2): 431-439, 2009

Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). European Journal of Cardiovascular Prevention and Rehabilitation 13(5): 776-783, 2006

Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses. Cadth Technology Overviews 1(3): E0121-E0121, 2010

Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era. International Journal of Cardiology. Heart and Vasculature 8: 154-160, 2015

Good practice in occupational health services--Certification of stroke as an accident at work. Need for secondary prevention in people returning to work after acute cerebrovascular events. Medycyna Pracy 66(4): 595-599, 2016

Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Journal of Cardiovascular Pharmacology and Therapeutics 10(3): 153-161, 2005

Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Journal of Thrombosis and Thrombolysis 22(1): 71-76, 2006

Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 39(9): 2444-2448, 2008

Clinical-Epidemiological Profile of Patients Initiating Intensive Statin Therapy for the Secondary Prevention of Vascular Disease in Spain. Revista Espanola de Salud Publica 89(2): 159-171, 2016

Secondary prevention of atherothrombotic cerebrovascular events. Current Vascular Pharmacology 12(3): 365-372, 2015